Advancements in Multiple Myeloma Care: Frontline Treatment Strategies in Newly Diagnosed Multiple Myeloma

Beth Faiman, PhD, CNP, discusses how to optimize treatment strategies for multiple myeloma patients by considering factors like transplant eligibility, risk stratification, and emerging clinical trial data from PERSEUS, MAIA, and CEPHEUS to guide decisions around initial therapy, maintenance approaches, and the use of novel drug combinations.

During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.